GeoVax Labs Statistics
Total Valuation
GeoVax Labs has a market cap or net worth of $3.19 million. The enterprise value is $371,668.
| Market Cap | 3.19M |
| Enterprise Value | 371,668 |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GeoVax Labs has 9.09 million shares outstanding. The number of shares has increased by 439.21% in one year.
| Current Share Class | 9.09M |
| Shares Outstanding | 9.09M |
| Shares Change (YoY) | +439.21% |
| Shares Change (QoQ) | +127.34% |
| Owned by Insiders (%) | 6.06% |
| Owned by Institutions (%) | 9.18% |
| Float | 8.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.47 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.54, with a Debt / Equity ratio of 0.18.
| Current Ratio | 1.54 |
| Quick Ratio | 1.16 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -891.59% and return on invested capital (ROIC) is -523.18%.
| Return on Equity (ROE) | -891.59% |
| Return on Assets (ROA) | -256.80% |
| Return on Invested Capital (ROIC) | -523.18% |
| Return on Capital Employed (ROCE) | -1,063.58% |
| Weighted Average Cost of Capital (WACC) | 22.10% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.08M |
| Employee Count | 19 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.84% in the last 52 weeks. The beta is 3.65, so GeoVax Labs's price volatility has been higher than the market average.
| Beta (5Y) | 3.65 |
| 52-Week Price Change | -97.84% |
| 50-Day Moving Average | 0.63 |
| 200-Day Moving Average | 1.93 |
| Relative Strength Index (RSI) | 24.68 |
| Average Volume (20 Days) | 347,546 |
Short Selling Information
The latest short interest is 367,575, so 4.04% of the outstanding shares have been sold short.
| Short Interest | 367,575 |
| Short Previous Month | 182,364 |
| Short % of Shares Out | 4.04% |
| Short % of Float | 4.30% |
| Short Ratio (days to cover) | 0.33 |
Income Statement
| Revenue | n/a |
| Gross Profit | -15.05M |
| Operating Income | -20.53M |
| Pretax Income | -20.43M |
| Net Income | -20.43M |
| EBITDA | -20.47M |
| EBIT | -20.53M |
| Earnings Per Share (EPS) | -$8.75 |
Balance Sheet
The company has $3.14 million in cash and $323,141 in debt, with a net cash position of $2.82 million or $0.31 per share.
| Cash & Cash Equivalents | 3.14M |
| Total Debt | 323,141 |
| Net Cash | 2.82M |
| Net Cash Per Share | $0.31 |
| Equity (Book Value) | 1.76M |
| Book Value Per Share | 0.24 |
| Working Capital | 1.46M |
Cash Flow
| Operating Cash Flow | -18.37M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 59,184 |
| Net Borrowing | n/a |
| Free Cash Flow | -18.37M |
| FCF Per Share | -$2.02 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
GeoVax Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -439.21% |
| Shareholder Yield | -439.21% |
| Earnings Yield | -639.92% |
| FCF Yield | -575.50% |
Analyst Forecast
The average price target for GeoVax Labs is $10.00, which is 2,749.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 2,749.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 12, 2026. It was a reverse split with a ratio of 1:25.
| Last Split Date | Jan 12, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
GeoVax Labs has an Altman Z-Score of -60.48 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -60.48 |
| Piotroski F-Score | 1 |